только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 4 / 10
Страница 1 / 1

Список литературы

  1. Каприн А. Д., Рожкова Н. И. Маммология: национальное руководство //М.: Геотар- Медиа. – 2016., ГЭОТАР-Мед. Москва.
  2. Baer H. J. et al. Early life factors and incidence of proliferative benign breast disease //Cancer Epidemiology and Prevention Biomarkers. – 2005. – Т. 14. – №. 12. – С. 2889-2897.
  3. Berkey C. S. et al. Prospective study of growth and development in older girls and risk of benign breast disease in young women //Cancer. – 2011. – Т. 117. – №. 8. – С. 1612-1620.
  4. Baer H. J. et al. Adolescent diet and incidence of proliferative benign breast disease //Cancer Epidemiology and Prevention Biomarkers. – 2003. – Т. 12. – №. 11. – С. 1159-1167.
  5. Su X. et al. Intake of fiber and nuts during adolescence and incidence of proliferative benign breast disease //Cancer Causes & Control. – 2010. – Т. 21. – №. 7. – С. 1033-1046.
  6. Jung M. M. et al. Lifetime physical activity and the incidence of proliferative benign breast disease //Cancer Causes & Control. – 2011. – Т. 22. – №. 9. – С. 1297.
  7. Ader D. N. et al. Cyclical mastalgia: prevalence and associated health and behavioral factors //Journal of Psychosomatic Obstetrics & Gynecology. – 2001. – Т. 22. – №. 2. – С. 71-76.
  8. Rohan T. E., Miller A. B. Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast //European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP). – 1999. – Т. 8.
  9. O’Connell P. et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci //JNCI: Journal of the National Cancer Institute. – 1998. – Т. 90. – №. 9. – С. 697-703.
  10. Hoogerbrugge-van der Linden N. et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. – 2003.
  11. Беспалов В. Г., Травина М. Л. Фиброзно-кистозная болезнь и риск рака молочной железы (обзор литературы) //Опухоли женской репродуктивной системы. – 2015. – №. 4.
  12. Прилепская В. Н., Швецова О. Б. Доброкачественные заболевания молочных желез: принципы терапии В помощь практическому врачу //Гинекология. – 2000. – Т. 2. – №. 6. – С. 201-204.
  13. Радзинский В. Е. Молочные железы и гинекологические болезни. – 2010.
  14. Silvera S. A. N., Rohan T. E. Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence //Breast cancer research and treatment. – 2008. – Т. 110. – №. 3. – С. 397-409.
  15. Dyrstad S. W. et al. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis //Breast cancer research and treatment. – 2015. – Т. 149. – № . 3. – С. 569-575.
  16. Onstad M., Stuckey A. Benign breast disorders //Obstetrics and Gynecology Clinics. – 2013. – Т. 40. – №. 3. – С. 459-473.
  17. Mendell L., Rosenbloom M., Naimark A. Are breast patterns a risk index for breast cancer? A reappraisal //American Journal of Roentgenology. – 1977. – Т. 128. – №. 4. – С. 547-547.
  18. Boyd N. F. et al. Bias and the association of mammographic parenchymal patterns with breast cancer //British journal of cancer. – 1982. – Т. 45. – №. 2. – С. 179.
  19. Brisson J., Morrison A. S., Khalid N. Mammographic parenchymal features and breast cancer in the breast cancer detection demonstration project //JNCI: Journal of the National Cancer Institute. – 1988. – Т. 80. – №. 19. – С. 1534-1540.
  20. Janzon L., Andersson I., Petersson H. Mammographic patterns as indicators of risk of breast cancer. A cross-sectional population study //Radiology. – 1982. – Т. 143. – №. 2. – С. 417-419.
  21. Byrne C. et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status //JNCI: Journal of the National Cancer Institute. – 1995. – Т. 87. – № . 21. – С. 1622-1629.
  22. Fitzgibbons P. L., Henson D. E., Hutter R. V. P. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement //Archives of pathology & laboratory medicine. – 1998. – Т. 122. – №. 12. – С. 1053.
  23. Smith R. L., Pruthi S., Fitzpatrick L. A. Evaluation and management of breast pain //Mayo Clinic Proceedings. – Elsevier, 2004. – Т. 79. – №. 3. – С. 353-372.
  24. Noroozian M. et al. Long-term clinical outcomes in women with breast pain in the absence of additional clinical findings: mammography remains indicated //Breast cancer research and treatment. – 2015. – Т. 149. – №. 2. – С. 417-424.
  25. Plu-Bureau G. et al. Cyclical mastalgia and breast cancer risk: results of a French cohort study //Cancer Epidemiology and Prevention Biomarkers. – 2006. – Т. 15. – №. 6. – С. 1229-1231.
  26. Мастопатии / [Андреева Е. Н., Боженко В. К., Бурдина И. И. и др.] ; под редакцией А. Д. Каприна, Н. И. Рожковой. - Москва : ГЭОТАР-Медиа, 2019.
  27. Савельева Г. М. и др. Национальное руководство //Акушерство–М.: Гэотар-Медиа. – 2015.
  28. Ngo C., Seror J., Chabbert-Buffet N. Breast pain: recommendations //Journal de gynecologie, obstetrique et biologie de la reproduction. – 2015. – Т. 44. – №. 10. – С. 938-946.
  29. Bevers T. B. et al. Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology //Journal of the National Comprehensive Cancer Network. – 2018. – Т. 16. – №. 11. – С. 1362-1389.
  30. Gorins A., Cordray J. P. Hormonal profile of benign breast disease and premenstrual mastodynia //European journal of gynaecological oncology. – 1984. – Т. 5. – №. 1. – С. 1-10.
  31. Mancini A. et al. Endocrine evaluation of patients with benign lumps of the breast //Cancer detection and prevention. – 1992. – Т. 16. – №. 1. – С. 27-30.
  32. Lauby-Secretan B. et al. Breast-cancer screening—viewpoint of the IARC Working Group //New England journal of medicine. – 2015. – Т. 372. – №. 24. – С. 2353-2358.
  33. Speroff L., Fritz M. A. (ed.). Clinical gynecologic endocrinology and infertility. – lippincott Williams & wilkins, 2011.
  34. Сметник В. П., Тумилович Л. Г. Неоперативная гинекология. – Медицинское информационное агентство, 2006.
  35. Diagnosis and management of benign breast disorders. Clinical management guidelines for obstetrician-gynecologists., Obstetrics & Gynecology., no. 127(6), pp. 141–156, 2016.
  36. Рожкова Н. И. Рентгенодиагностика заболеваний молочной железы. – 1993., Медицина. Москва.
  37. Henderson T. O. et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer //Annals of internal medicine. – 2010. – Т. 152. – №. 7. – С. 444-455.
  38. Mahesh M. The AAPM/RSNA physics tutorial for residents: search for isotropic resolution in CT from conventional through multiple-row detector //Radiographics. – 2002. – Т. 22. – №. 4. – С. 949-962.
  39. Sardanelli F. et al. Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estoni.
  40. Buchberger W. et al. Incidental findings on sonography of the breast: clinical significance and diagnostic workup //AJR. American journal of roentgenology. – 1999. – Т. 173. – №. 4. – С. 921- 927.
  41. Якобс О. Э., Рожкова Н. И., Каприн А. Д. Возможности соноэластографии при дифференциальной диагностике заболеваний молочной железы, сопровождающихся скоплением микрокальцинатов //Акушерство и гинекология: Новости. Мнения. Обучения. – 2017. – №. 1 (15).
  42. Якобс, О. Э. Оптимизация ранней диагностики непальпируемого рака молочной железы на основе интеграции цифровых радиологических технологий //Автореф..дисс., докт мед наук., 2019.
  43. Catalano O. et al. Additional role of colour Doppler ultrasound imaging in intracystic breast tumours //La radiologia medica. – 2009. – Т. 114. – №. 2. – С. 253.
  44. Itoh A. et al. Breast disease: clinical application of US elastography for diagnosis //Radiology. – 2006. – Т. 239. – №. 2. – С. 341-350.
  45. C. Weismann, C. Mayr, H. Egger, and A. Auer. Breast Sonography – 2D, 3D, 4D Ultrasound or Elastography? Breast Care, vol. 6, no. 2, pp. 98–103, 2011, doi: 10.1159/000327504.
  46. Lehman C. D. et al. Diagnostic accuracy of digital screening mammography with and without computer-aided detection //JAMA internal medicine. – 2015. – Т. 175. – №. 11. – С. 1828-1837.
  47. Серов В. Н. и др. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии //М.: ГЭОТАР-Медиа. – 2016., ГЭОТАР-Мед. Москва.
  48. Серов В. Н., Сухих Г. Т. Клинические рекомендации. Акушерство и гинекология //М: ГЭОТАР-Медиа.-4-е изд.-2017. Москва: Проблемы репродукции.
  49. Heywang-Köbrunner S. H. et al. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions //European journal of radiology. – 1997. – Т. 24. – №. 2. – С. 94-108.
  50. Kriege M. et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition //New England Journal of Medicine. – 2004. – Т. 351. – №. 5. – С. 427-437.
  51. Корженкова Г. П. Диагностическое значение категорий BI-RADS в ведении пациенток с доброкачественной патологией молочных желез //Опухоли женской репродуктивной системы. – 2016. – №. 4.
  52. ACR Breast Imaging Reporting and Data System, Breast Imaging Atlas; BI-RADS. Reston, VA: American College of Radiology.// American College of Radiology (ACR). ACR-BI-RADS®--5th Edition., 2014.
  53. Harvey J. A. et al. Short-term follow-up of palpable breast lesions with benign imaging features: evaluation of 375 lesions in 320 women //American Journal of Roentgenology. – 2009. – Т. 193. – №. 6. – С. 1723-1730.
  54. Patterson S. K. et al. Outcomes of solid palpable masses assessed as BI-RADS 3 or 4A: a retrospective review //Breast cancer research and treatment. – 2014. – Т. 147. – №. 2. – С. 311-316.
  55. Graf O. et al. Follow-up of palpable circumscribed noncalcified solid breast masses at mammography and US: can biopsy be averted? //Radiology. – 2004. – Т. 233. – №. 3. – С. 850-856.
  56. Shin J. H. et al. Probably benign breast masses diagnosed by sonography: is there a difference in the cancer rate according to palpability? //American journal of roentgenology. – 2009. – Т. 192. – №. 4. – С. W187-W191.
  57. Huff J. G. The sonographic findings and differing clinical implications of simple, complicated, and complex breast cysts //Journal of the National Comprehensive Cancer Network. – 2009. – Т. 7. – №. 10. – С. 1101-1105.
  58. Daly C. P. et al. Complicated breast cysts on sonography: is aspiration necessary to exclude malignancy? //Academic radiology. – 2008. – Т. 15. – №. 5. – С. 610-617.
  59. Venta L. A. et al. Management of complex breast cysts //AJR. American journal of roentgenology. – 1999. – Т. 173. – №. 5. – С. 1331-1336.
  60. Doshi D. J. et al. Complex cystic breast masses: diagnostic approach and imaging-pathologic correlation //Radiographics. – 2007. – Т. 27. – №. suppl_1. – С. S53-S64.
  61. Shetty M. K., Shah Y. P. Prospective evaluation of the value of negative sonographic and mammographic findings in patients with palpable abnormalities of the breast //Journal of ultrasound in medicine. – 2002. – Т. 21. – №. 11. – С. 1211-1220.
  62. Moy L. et al. Specificity of mammography and US in the evaluation of a palpable abnormality: retrospective review //Radiology. – 2002. – Т. 225. – №. 1. – С. 176-181.
  63. Leung S. E., Ben-Nachum I., Kornecki A. New Palpable Breast Lump With Recent Negative Mammogram: Is Repeat Mammography Necessary? //American Journal of Roentgenology. – 2016. – Т. 207. – №. 1. – С. 200-204.
  64. Гарифуллова Ю. В. Лучевые методы диагностики доброкачественных заболеваний молочных желез //Практическая медицина. – 2017. – №. 7 (108).
  65. Hussain A. N., Policarpio C., Vincent M. T. Evaluating nipple discharge //Obstetrical & gynecological survey. – 2006. – Т. 61. – №. 4. – С. 278-283.
  66. Jain A. et al. Management of nipple discharge: technology chasing application //The breast journal. – 2010. – Т. 16. – №. 4. – С. 451-452.
  67. Tokuda Y. et al. Evaluation of suspicious nipple discharge by magnetic resonance mammography based on breast imaging reporting and data system magnetic resonance imaging descriptors //Journal of computer assisted tomography. – 2009. – Т. 33. – №. 1.
  68. Ballesio L. et al. Role of breast magnetic resonance imaging (MRI) in patients with unilateral nipple discharge: preliminary study //La radiologia medica. – 2008. – Т. 113. – №. 2. – С. 249-264.
  69. Ashfaq A. et al. Validation study of a modern treatment algorithm for nipple discharge //The American Journal of Surgery. – 2014. – Т. 208. – №. 2. – С. 222-227.
  70. Abati A., Simsir A. Breast fine needle aspiration biopsy: prevailing recommendations and contemporary practices //Clinics in laboratory medicine. – 2005. – Т. 25. – №. 4. – С. 631-654.
  71. P. Levine, A. Simsir, and J. Cangiarella, “Management Issues in Breast Lesions Diagnosed by Fine-Needle Aspiration and Percutaneous Core Breast Biopsy,” Pathol. Patterns Rev., vol. 125, no. suppl_1, pp. S124–S134, Jun. 2006.
  72. Rosolowich V. et al. Mastalgia //Journal of Obstetrics and Gynaecology Canada. – 2006. – Т. 28. – №. 1. – С. 49-57.
  73. B. R. Mason, K.-A. Page, and K. Fallon, Mason B. R., Page K. A., Fallon K. An analysis of movement and discomfort of the female breast during exercise and the effects of breast support in three cases //Journal of Science and Medicine in Sport. – 1999. – Т. 2. – №. 2. – С. 134-144.
  74. Yeow K. M. et al. Ultrasound-guided core needle biopsy as an initial diagnostic test for palpable breast masses //Journal of Vascular and Interventional Radiology. – 2001. – Т. 12. – №. 11. – С. 1313-1317.
  75. Egyed Z. et al. Radial scar-significant diagnostic challenge //Pathology & Oncology Research. – 2008. – Т. 14. – №. 2. – С. 123.
  76. Murshid K. R. A review of mastalgia in patients with fibrocystic breast changes and the non- surgical treatment options //Journal of Taibah University Medical Sciences. – 2011. – Т. 6. – №. 1. – С. 1-18.
  77. Fox H. et al. Are patients with mastalgia anxious, and does relaxation therapy help? //The Breast. – 1997. – Т. 6. – №. 3. – С. 138-142.
  78. Barros A. C. S. D. et al. Reassurance in the treatment of mastalgia //The breast journal. – 1999. – Т. 5. – №. 3. – С. 162-165.
  79. Родионов В. В., Сметник А. А. Доброкачественные заболевания молочных желез // Акушерство и гинекология: Новости. Мнения. Обучения. – 2018. – №. 1 (19). .
  80. Faiz O., Fentiman I. S. Management of breast pain //International journal of clinical practice. – 2000. – Т. 54. – №. 4. – С. 228-232.
  81. Goodwin P. J. et al. Elevated high-density lipoprotein cholesterol and dietary fat intake in women with cyclic mastopathy //American journal of obstetrics and gynecology. – 1998. – Т. 179. – №. 2. – С. 430-437.
  82. Boyd N. F. et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial //Journal of the National Cancer Institute. – 1997. – Т. 89. – №. 7. – С. 488-496.
  83. Рожкова Н. И., Меских Е. В. Применение Мастодинона при различных формах мастопатии //Опухоли женской репродуктивной системы. – 2010. – №. 3.
  84. Halaska M. et al. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study //The Breast. – 1999. – Т. 8. – №. 4. – С. 175-181.
  85. Ooi S. L. et al. Vitex agnus-castus for the treatment of cyclic mastalgia: a systematic review and meta-analysis //Journal of Women’s Health. – 2019.
  86. Winkler U. H. et al. Cyclic progestin therapy for the management of mastopathy and mastodynia //Gynecological Endocrinology. – 2001. – Т. 15. – №. sup6. – С. 37-43.
  87. Меских Е. В., Рожкова Н. И. Применение прожестожеля при диффузных формах мастопатии //Опухоли женской репродуктивной системы. – 2012. – №. 1.
  88. КОГАН И. Ю., Мусина Е. В. Местное применение микронизированного прогестерона у больных репродуктивного возраста с мастопатией //Акушерство и гинекология. – 2012. – №. 2. – С. 102-106.
  89. Муйжнек Е. Л. и др. Фибросклероз и склерозирующий аденоз с микрокальцинатами в молочной железе. Молекулярный патогенез, своевременная диагностика и лечение //Research’n Practical Medicine Journal. – 2019. – Т. 6. – №. 2.
  90. КИСЕЛЕВ В. И. и др. Индолкарбинол-метод мультитаргетной терапии при циклической мастодинии //Акушерство и гинекология. – 2013. – №. 7. – С. 56-63.
  91. Сметник А. А., Сметник В. П., Киселев В. И. Опыт применения индол-3-карбинола в лечении заболеваний молочной железы и профилактике рака молочной железы // Акушерство и гинекология. – 2017. – №. 2. – С. 106-112.
  92. Синицын В. А., Руднева Т. В. Лечение больных с фиброзно-кистозной мастопатией, сопровождающейся болевым синдромом //Рос вестн акуш гинекол. – 2006. – Т. 2. – С. 1-2.
  93. Wuttke W. et al. Behandlung zyklusabhängiger Brustschmerzen mit einem Agnus castus- haltigen Arzneimittel //Geburtshilfe und Frauenheilkunde. – 1997. – Т. 57. – №. 10. – С. 569-574.
  94. Высоцкая И. В., Летягин В. П. Атипичные гиперплазии молочной железы //Опухоли женской репродуктивной системы. – 2015. – №. 4.
  95. Высоцкая И. В. Современные возможности терапии фиброзно-кистозной болезни // Опухоли женской репродуктивной системы. – 2009. – №. 1-2.
  96. Santen R. J., Mansel R. Benign breast disorders //New England Journal of Medicine. – 2005. – Т. 353. – №. 3. – С. 275-285.
  97. Coutant C. et al. Benign proliferative breast disease with and without atypia //Journal de gynecologie, obstetrique et biologie de la reproduction. – 2015. – Т. 44. – №. 10. – С. 980-995.
  98. Foulkes R. E. et al. Duct excision is still necessary to rule out breast cancer in patients presenting with spontaneous bloodstained nipple discharge //International journal of breast cancer. – 2011. – Т. 2011.
  99. Высоцкая И. В. и др. Клинические рекомендации Российского общества онкомаммологов по профилактике рака молочной железы, дифференциальной диагностике, лечению предопухолевых и доброкачественных заболеваний молочных желез //Опухоли женской репродуктивной системы. – 2016. – №. 3.
  100. Kjartansdottir O. J. et al. Estrogen–progestin use and breast cancer characteristics in lean and overweight postmenopausal women //Breast cancer research and treatment. – 2017. – Т. 163. – №. 2. – С. 363-373.
  101. Kaiser J. S. et al. Palpable breast thickening: role of mammography and US in cancer detection //Radiology. – 2002. – Т. 223. – №. 3. – С. 839-844.
  102. White A. J. et al. Lifetime alcohol intake, binge drinking behaviors, and breast cancer risk //American journal of epidemiology. – 2017. – Т. 186. – №. 5. – С. 541-549.
  103. Yenen M.C. et al. Hormone replacement therapy in postmenopausal women with benign fibrocystic mastopathy // Climacteric. – 2003. – №6(2). – С. 146-150.
  104. Lubin F. et al. Nutritional factors associated with benign breast disease etiology: a case- control study //The American journal of clinical nutrition. – 1989. – Т. 50. – №. 3. – С. 551-556.
  105. Collaborative Group on Hormonal Factors in Breast Cancer et al. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease //The lancet. – 2002. – Т. 360. – №. 9328. – С. 187-195.
  106. De Felice F. et al. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis //Annals of surgical oncology. – 2015. – Т. 22. – №. 9. – С. 2876-2880.
  107. Loving V. A. et al. Targeted ultrasound in women younger than 30 years with focal breast signs or symptoms: outcomes analyses and management implications //American Journal of Roentgenology. – 2010. – Т. 195. – №. 6. – С. 1472-1477.
  108. 2015. WHO, “Medical eligibility criteria for contraceptive use.”
  109. Curtis K. M. et al. US medical eligibility criteria for contraceptive use, 2016. – 2016.
  110. Wang K. et al. Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies //Oncotarget. – 2017. – Т. 8. – №. 46. – С. 81109.
  111. Román M. et al. Postmenopausal hormone therapy and breast cancer prognostic characteristics: a linkage between nationwide registries //Cancer Epidemiology and Prevention Biomarkers. – 2016. – Т. 25. – №. 11. – С. 1464-1473.
  112. Сухих Г. Т. и др. Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста. Клинические рекомендации: протоколы //Клинические рекомендации (протокол лечения)./ГТ Сухих, ВП Сметник, ЕН Андреева− М. – 2015. – С. 30.
  113. Liu Y. et al. Intakes of alcohol and folate during adolescence and risk of proliferative benign breast disease //Pediatrics. – 2012. – Т. 129. – №. 5. – С. e1192-e1198.
  114. Frazier A. L., Rosenberg S. M. Preadolescent and adolescent risk factors for benign breast disease //Journal of Adolescent Health. – 2013. – Т. 52. – №. 5. – С. S36-S40.
  115. Cui Y. et al. Menstrual and reproductive history, postmenopausal hormone use, and risk of benign proliferative epithelial disorders of the breast: a cohort study //Breast cancer research and treatment. – 2009. – Т. 114. – №. 1. – С. 113-120.
  116. Lauby-Secretan B. et al. Body fatness and cancer—viewpoint of the IARC Working Group //New England Journal of Medicine. – 2016. – Т. 375. – №. 8. – С. 794-798.
  117. Heinemann K. et al. Benign gynecological tumors: estimated incidence: results of the German Cohort Study on Women’s Health //European Journal of Obstetrics & Gynecology and Reproductive Biology. – 2003. – Т. 107. – №. 1. – С. 78-80.
  118. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” CA. Cancer J. Clin., vol. 67, no. 1, pp. 7–30, Jan. 2017, doi: 10.3322/caac.21387.
  119. Ritte R. et al. Height, age at menarche and risk of hormone receptor‐positive and‐negative breast cancer: A cohort study //International journal of cancer. – 2013. – Т. 132. – №. 11. – С. 2619- 2629.
  120. Eliassen A. H. et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women //Journal of the National Cancer Institute. – 2006. – Т. 98. – №. 19. – С. 1406-1415.
  121. Kerlikowske K. et al. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk //Journal of the National Cancer Institute. – 2007. – Т. 99. – №. 5. – С. 386-395.
  122. Qu X. et al. Bone mineral density and risk of breast cancer in postmenopausal women //Breast cancer research and treatment. – 2013. – Т. 138. – №. 1. – С. 261-271.
  123. Kaaks R. et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC) //Journal of the National Cancer Institute. – 2005. – Т. 97. – №. 10. – С. 755-765.
  124. Hormones T. E. et al. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies //The lancet oncology. – 2010. – Т. 11. – №. 6. – С. 530-542.
  125. Gunter M. J. et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women //Journal of the National Cancer Institute. – 2009. – Т. 101. – №. 1. – С. 48-60.
  126. Nichols H. B. et al. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006 //Journal of Clinical Oncology. – 2011. – Т. 29. – №. 12. – С. 1564.
  127. Kuchenbaecker K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers //Jama. – 2017. – Т. 317. – №. 23. – С. 2402-2416.
  128. Gram I. T. et al. Smoking and risk of breast cancer in a racially/ethnically diverse population of mainly women who do not drink alcohol: the MEC Study //American journal of epidemiology. – 2015. – Т. 182. – №. 11. – С. 917-925.

Для продолжения работы требуется вход / регистрация